Positron emission tomography (PET) is a molecular imaging technique that allows quantification of brain pathophysiological changes in Alzheimer’s and other neurodegenerative diseases. PET tracers for amyloid plaque deposition and glucose metabolism have been approved for clinical use in the recent years, and are increasingly used as biomarkers for early diagnose or to track disease progression, with important application in clinical trials. Increasing evidence suggests that the pathology and clinical presentation of Alzheimer’s disease is highly heterogeneous, and research on multiple biomarkers is crucial to understanding its complex neurobiology, including abnormal deposition of tau tangles and alpha-synuclein inclusions. This presentation will describe ongoing PET imaging research on the associations and time courses of different proteinopathies from very early presymptomatic stages, towards elucidating the interactive processes leading to disease onset and progression of Alzheimer’s disease.


Elena Rodriguez-Vieitez , Center for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Novum
Telefon:070 995 9016
E-post: elena.rodriguez-vieitez@ki.se
Websida: http://ki.se/en/people/elerod


Kalicharan Patra, Institutionen för neurokemi